NIH × Ipilimumab × Gynecologic × Clear all
NCT02834013 2026-03-18

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
818 enrolled
NCT00039091 2018-09-05

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
26 enrolled
NCT00060372 2013-03-27

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled